An analysis of the attrition of drug candidates from four major pharmaceutical companies

@article{Waring2015AnAO,
  title={An analysis of the attrition of drug candidates from four major pharmaceutical companies},
  author={M. Waring and J. Arrowsmith and A. Leach and P. Leeson and Sam Mandrell and R. M. Owen and G. Pairaudeau and W. Pennie and S. Pickett and Jibo Wang and Owen Wallace and A. Weir},
  journal={Nature Reviews Drug Discovery},
  year={2015},
  volume={14},
  pages={475-486}
}
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. [...] Key Result The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to…Expand

Figures, Tables, and Topics from this paper

Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
TLDR
Comprehensive industry-wide data on the mechanism–indication pairs that have been investigated during the past 20 years are analyzed, including areas in which the industry has had substantial success or failure and the relative extent of novelty in completed and ongoing projects are examined. Expand
Molecular inflation, attrition and the rule of five.
  • P. Leeson
  • Medicine, Chemistry
  • Advanced drug delivery reviews
  • 2016
TLDR
Overall, there is demonstrable physical property attrition in moving from patents to candidate drugs to marketed drugs, and attrition can therefore be improved by ensuring candidate drug quality is 'fit for purpose. Expand
Is there enough focus on lipophilicity in drug discovery?
  • S. Lobo
  • Computer Science, Medicine
  • Expert opinion on drug discovery
  • 2019
TLDR
Increasing evidence suggests that monitoring lipophilicity may contribute significantly to the overall quality of candidate drugs at different stages of discovery and to reduced attrition; thus, a greater focus on lipophILicity, controlled within a defined optimal range, is warranted. Expand
Compound high-quality criteria: a new vision to guide the development of drugs, current situation.
TLDR
The development of the new guides to find drugs highlighting attempts at improving the attrition rate from hits to final medicines by focusing on how to improve the druggability of hits, leads and drugs during the drug discovery process represents a key approach to design next better generation of medicines. Expand
The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system
TLDR
This study is focused on the high attrition rate in discovery and development of oncology and central nervous system medicines, because the failure rate of these medicines is higher than others. Expand
Current trends in in silico, in vitro toxicology, and safety biomarkers in early drug development
TLDR
Innovation in de-risking strategies may support refinement of regulatory testing and contribute to improve drug safety evaluation alleviating assessment of the risk-benefit ratio and promote the access to safe drugs for patients. Expand
A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans
TLDR
The study confirmed the general predictivity of animal safety observations for humans, but also identified issues of such automated analyses which are on the one hand related to data curation and controlled vocabularies, on the other hand to methodological changes over the course of time. Expand
Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery.
This editorial summarizes the content of the current themed issue of J Pharm Tox Methods derived from the 2019 Annual Safety Pharmacology Society (SPS) meeting held in Barcelona, Spain, and reflectsExpand
Improving the assessment of the probability of success in late stage drug development
There are several steps to confirming the safety and efficacy of a new medicine. A sequence of trials, each with its own objectives, is usually required. Quantitative risk metrics can be useful forExpand
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
TLDR
Highlights and case studies of lessons learned from discovery of bRo5 compounds are presented and a simple multiparametric scoring function (AB-MPS) was devised that correlated preclinical PK results with cLogD, number of rotatable bonds, and number of aromatic rings. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
TLDR
For the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies are presented and illustrated with examples of their impact on the drug discovery process. Expand
The influence of the 'organizational factor' on compound quality in drug discovery
TLDR
It is concluded that a substantial sector of the pharmaceutical industry has not modified its drug design practices and is still producing compounds with suboptimal physicochemical profiles. Expand
A critical assessment of modeling safety-related drug attrition
TLDR
An analysis of 150 AstraZeneca development compounds and some of the published guidelines and their ability to identify compounds with safety liabilities found that a large portion did not comply and would never have reached patients if such guidelines had been applied at an early stage. Expand
The influence of drug-like concepts on decision-making in medicinal chemistry
TLDR
Analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. Expand
Lipophilicity in drug discovery
  • M. Waring
  • Chemistry, Medicine
  • Expert opinion on drug discovery
  • 2010
TLDR
The aim is to provide an overview of the relevant literature in an attempt to summarise where the optimum region of lipophilicity lies and to highlight which particular issues and risks might be expected when operating outside this region. Expand
Probing the links between in vitro potency, ADMET and physicochemical parameters
TLDR
Key findings include: first, that oral drugs seldom possess nanomolar potency; second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose. Expand
Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies.
TLDR
The most predictive end point contributing to compound survival was a predicted human efficacious concentration of ≤250 nM and ≤40 nM, encompassing targets such as enzymes, G-protein-coupled receptors, ion channels, and transporters. Expand
Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes.
TLDR
This work examines the relationship between molecular properties and in vitro surrogate assays vs in vivo properties within 173 chemical series from a database of 3773 compounds with rodent pharmacokinetic and toxicology data and identifies the following pairs of surrogates as most predictive among those examined. Expand
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
TLDR
A comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010 allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which are described as the five 'R's'. Expand
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.
TLDR
A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacological activity all determine the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III. Expand
...
1
2
3
...